The future of stroke thrombolysis

Area of Science:

• Neurology
• Emergency Medicine
• Pharmacology

Background:

• Tissue plasminogen activator (t-PA) significantly improves stroke outcomes when given within 3 hours of onset.
• Current t-PA administration rates in North America are below 5%, indicating a critical gap in stroke care.
• This disparity necessitates exploring strategies to enhance t-PA utilization for ischemic stroke patients.

Purpose of the Study:

• To investigate methods for increasing the administration of t-PA in stroke patients.
• To analyze successful implementation strategies from Canadian stroke centers.
• To review novel approaches for expanding t-PA eligibility and delivery.

Main Methods:

• Examined Canadian audit data on t-PA administration rates in regional stroke centers.
• Reviewed potential for expanded physician use of t-PA, including remote Telestroke applications.
• Assessed the use of imaging characteristics versus stroke onset time for t-PA eligibility determination.

Main Results:

• Canadian audit showed 8.2% of ischemic stroke patients received t-PA.
• In Ontario regional stroke centers, 42.2% of eligible patients arriving within 2.5 hours received t-PA.
• Identified potential for expanded t-PA use through Telestroke and revised eligibility criteria.

Conclusions:

• Implementing targeted strategies can significantly improve t-PA administration rates in stroke care.
• Expanding t-PA delivery via Telestroke and utilizing advanced imaging can broaden patient access.
• Further research into combining t-PA with immune modulation may enhance stroke treatment efficacy.